TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Edwards Lifesciences; Abbott</li></ul>